Research with human tissue and cells suggests that genetic variations, in addition to failure to comply with treatment regimens, may account for some failures of an anti-HIV drug to treat and prevent HIV infection.
Jul 9, 2015
0
11
Data revealed today at The International Liver Congress 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with ...
Apr 23, 2015
0
5
Researchers who conducted VOICE, a major HIV prevention trial involving more than 5,000 women in Africa, describe the study's primary results in this week's issue of the New England Journal of Medicine (NEJM), outlining in ...
Feb 4, 2015
0
4
A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection ...
Oct 30, 2014
0
0
The risk of acquiring herpes simplex virus type 2 (HSV-2) was reduced by half among women in the VOICE trial who used a vaginal gel containing the antiretroviral (ARV) drug tenofovir regularly, according to researchers from ...
Oct 28, 2014
0
0
For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more ...
May 5, 2014
0
0
Women's reproductive health may never be the same, thanks to Northwestern University biomedical engineer Patrick Kiser and his first-of-its-kind intravaginal ring that reliably delivers an antiretroviral drug and a contraceptive ...
Mar 5, 2014
0
0
A new analysis by researchers from the U.S. National Institutes of Health-funded Microbicide Trials Network (MTN) confirms what they and many others had already assumed: The behavioral measures used for assessing adherence ...
Mar 4, 2014
0
0
A new intravaginal ring (IVR) has been developed for the sustained 90-day co-delivery of tenofovir and levonorgestrel, an anti-human immunodeficiency virus (HIV) drug and a contraceptive. Tenofovir is the only topical prophylactic ...
Nov 12, 2013
0
0
(HealthDay)—For patients with HIV-1 infection and HIV-1 RNA of 1,000 copies per mL or more, treatment with dolutegravir plus abacavir-lamivudine (DTG-ABC-3TC) is more effective through 48 weeks than combination therapy ...
Nov 7, 2013
0
0
